Repligen Corporation (RGEN) Upgraded by Piper Jaffray Companies to Overweight

Piper Jaffray Companies upgraded shares of Repligen Corporation (NASDAQ:RGEN) from a neutral rating to an overweight rating in a research note issued to investors on Monday morning. Piper Jaffray Companies currently has $3.57 price objective on the stock.

RGEN has been the topic of a number of other reports. Zacks Investment Research lowered shares of Repligen Corporation from a buy rating to a hold rating in a research report on Thursday, January 26th. Jefferies Group LLC restated a hold rating and set a $30.00 target price (up from $28.00) on shares of Repligen Corporation in a research report on Wednesday, December 21st. Finally, Stephens set a $37.00 target price on shares of Repligen Corporation and gave the stock a buy rating in a research report on Sunday, December 18th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $26.64.

Repligen Corporation (NASDAQ:RGEN) opened at 30.07 on Monday. The firm’s 50-day moving average is $30.56 and its 200-day moving average is $30.90. Repligen Corporation has a 52-week low of $21.11 and a 52-week high of $34.06. The stock has a market cap of $1.02 billion, a P/E ratio of 145.27 and a beta of 1.58.

TRADEMARK VIOLATION NOTICE: “Repligen Corporation (RGEN) Upgraded by Piper Jaffray Companies to Overweight” was published by sleekmoney and is the property of of sleekmoney. If you are viewing this piece on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece can be accessed at http://sleekmoney.com/repligen-corporation-rgen-upgraded-by-piper-jaffray-companies-to-overweight/1657760.html.

In related news, CEO Anthony Hunt sold 5,000 shares of Repligen Corporation stock in a transaction on Monday, November 28th. The shares were sold at an average price of $33.12, for a total value of $165,600.00. Following the transaction, the chief executive officer now directly owns 68,342 shares in the company, valued at approximately $2,263,487.04. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 2.30% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Teacher Retirement System of Texas raised its position in Repligen Corporation by 21.2% in the second quarter. Teacher Retirement System of Texas now owns 4,668 shares of the company’s stock worth $128,000 after buying an additional 818 shares during the period. Municipal Employees Retirement System of Michigan raised its position in Repligen Corporation by 1.6% in the third quarter. Municipal Employees Retirement System of Michigan now owns 7,460 shares of the company’s stock worth $225,000 after buying an additional 120 shares during the period. Aperio Group LLC raised its position in Repligen Corporation by 1.9% in the third quarter. Aperio Group LLC now owns 8,200 shares of the company’s stock worth $248,000 after buying an additional 151 shares during the period. Legal & General Group Plc raised its position in Repligen Corporation by 33.7% in the second quarter. Legal & General Group Plc now owns 9,009 shares of the company’s stock worth $240,000 after buying an additional 2,272 shares during the period. Finally, Columbus Circle Investors purchased a new position in Repligen Corporation during the third quarter worth $357,000. Hedge funds and other institutional investors own 94.35% of the company’s stock.

Repligen Corporation Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, production and commercialization of products used in the process of manufacturing biologic drugs (bioprocessing). The Company is a manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug.

5 Day Chart for NASDAQ:RGEN

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/repligen-corporation-rgen-upgraded-by-piper-jaffray-companies-to-overweight/1657760.html

Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *